CZ20012502A3 - Funkcionalizované heterocykly jako modulátory chemokinových receptorů - Google Patents

Funkcionalizované heterocykly jako modulátory chemokinových receptorů Download PDF

Info

Publication number
CZ20012502A3
CZ20012502A3 CZ20012502A CZ20012502A CZ20012502A3 CZ 20012502 A3 CZ20012502 A3 CZ 20012502A3 CZ 20012502 A CZ20012502 A CZ 20012502A CZ 20012502 A CZ20012502 A CZ 20012502A CZ 20012502 A3 CZ20012502 A3 CZ 20012502A3
Authority
CZ
Czechia
Prior art keywords
benzopyrano
quinolizine
decahydro
carboxylic acid
methyl
Prior art date
Application number
CZ20012502A
Other languages
Czech (cs)
English (en)
Inventor
Geraldine Harriman
Christine Nylund Kolz
Jay R. Luly
Bruce David Roth
Yuntao Song
Bharat Kalidas Trivedi
Original Assignee
Millennium Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals, Inc. filed Critical Millennium Pharmaceuticals, Inc.
Publication of CZ20012502A3 publication Critical patent/CZ20012502A3/cs

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D455/00Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CZ20012502A 1999-01-13 1999-12-20 Funkcionalizované heterocykly jako modulátory chemokinových receptorů CZ20012502A3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11565499P 1999-01-13 1999-01-13

Publications (1)

Publication Number Publication Date
CZ20012502A3 true CZ20012502A3 (cs) 2002-03-13

Family

ID=22362668

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20012502A CZ20012502A3 (cs) 1999-01-13 1999-12-20 Funkcionalizované heterocykly jako modulátory chemokinových receptorů

Country Status (20)

Country Link
EP (1) EP1144415A2 (ko)
JP (1) JP2002534526A (ko)
KR (1) KR20010086166A (ko)
CN (1) CN1344270A (ko)
AP (1) AP2001002228A0 (ko)
AU (1) AU1940900A (ko)
BR (1) BR9916905A (ko)
CA (1) CA2372197A1 (ko)
CZ (1) CZ20012502A3 (ko)
EA (1) EA200100774A1 (ko)
HK (1) HK1044539A1 (ko)
HU (1) HUP0202932A3 (ko)
IL (1) IL144289A0 (ko)
MX (1) MXPA01007033A (ko)
NO (1) NO20013456L (ko)
OA (1) OA11820A (ko)
PL (1) PL349348A1 (ko)
SK (1) SK9972001A3 (ko)
WO (1) WO2000042045A2 (ko)
ZA (1) ZA200106592B (ko)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072549A1 (en) * 2001-03-12 2002-09-19 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
DK1379239T3 (da) 2001-03-29 2008-01-07 Lilly Co Eli N(2-aryl-ethyl)-benzyl-aminer som antagonister af 5 HT6 receptoren
WO2003035650A1 (fr) * 2001-09-25 2003-05-01 Takeda Chemical Industries, Ltd. Inhibiteur d'entree
MXPA05009771A (es) 2003-03-14 2005-10-26 Ono Pharmaceutical Co Derivados heterociclicos que contienen nitrogeno y medicamentos que los contienen como el ingrediente activo.
WO2004092169A1 (ja) 2003-04-18 2004-10-28 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
AU2005283326B2 (en) 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
WO2006129679A1 (ja) 2005-05-31 2006-12-07 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
JP5251127B2 (ja) 2005-10-28 2013-07-31 小野薬品工業株式会社 塩基性基を含有する化合物およびその用途
PT1961744E (pt) 2005-11-18 2013-05-15 Ono Pharmaceutical Co Composto que contém um grupo básico e sua utilização
CN101460458A (zh) 2006-02-15 2009-06-17 阿勒根公司 具有1-磷酸-鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚-3-羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物
BRPI0707873A2 (pt) * 2006-02-15 2011-05-10 Allergan Inc compostos amida, Éster, tioamida e tiol Éster do Ácido indol-3-carboxÍlico carregando grupos arila ou heteroarila tendo atividade biolàgica antagonista de recptor de esfingosina-1-fosfato (s1p)
BRPI0708731A2 (pt) 2006-03-10 2011-06-07 Ono Pharmaceutical Co derivado heterocìclico nitrogenado, e agente farmacêutico compreendendo o derivado como ingrediente ativo
WO2007132846A1 (ja) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. 保護されていてもよい酸性基を含有する化合物およびその用途
US8329689B2 (en) 2006-05-23 2012-12-11 Alexandre Vasilievich Ivachtchenko Substituted indoles and a method for the production and use thereof
US20090325992A1 (en) 2006-07-31 2009-12-31 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
US8524917B2 (en) 2007-01-11 2013-09-03 Allergan, Inc. 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
CN101668741A (zh) 2007-01-11 2010-03-10 阿勒根公司 具有鞘氨醇-1-磷酸(s1p)受体拮抗剂生物学活性的6-取代吲哚-3-羧酸酰胺化合物
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
CN102958927A (zh) 2010-05-12 2013-03-06 Abbvie公司 激酶的吲唑抑制剂
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
CN104193669B (zh) * 2014-08-01 2016-12-07 大连理工大学 一类阿比朵尔类似物或其盐、其制备方法及应用
WO2016112088A1 (en) * 2015-01-06 2016-07-14 Spero Therapeutics, Inc. Aryloxyacetylindoles and analogs as antibiotic tolerance inhibitors
CN110256324A (zh) * 2019-06-13 2019-09-20 苏州莱安医药化学技术有限公司 一种2-甲基-5-羟基吲哚的制备方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3549641A (en) * 1966-06-28 1970-12-22 Warner Lambert Pharmaceutical Pyrano pyridines and process for their production
US3518258A (en) * 1967-05-09 1970-06-30 Warner Lambert Pharmaceutical Pyrano(3,2-i)quinolizine and process for the production
US3565903A (en) * 1967-11-24 1971-02-23 Warner Lambert Pharmaceutical Pyrano(2,3-b)quinolines and process for their production
US5635510A (en) * 1993-05-06 1997-06-03 Merrell Pharmaceuticals Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines
HRP960352A2 (en) * 1996-07-26 1998-08-31 Pliva Pharm & Chem Works Novel coumarin quinoline carboxylic acids
BR9807858A (pt) * 1997-02-26 2000-02-22 Pfizer Derivados de amida do ácido heteroaril-hexanóico, suas preparaçÊes e seus usos como inibidores seletios de mip-1.alfa ligando aos seus receptores ccr1
CA2319781A1 (en) * 1998-02-02 1999-08-05 Liping Wang Cyclic amine modulators of chemokine receptor activity

Also Published As

Publication number Publication date
OA11820A (en) 2005-08-17
KR20010086166A (ko) 2001-09-08
JP2002534526A (ja) 2002-10-15
AU1940900A (en) 2000-08-01
HK1044539A1 (zh) 2002-10-25
NO20013456L (no) 2001-09-12
AP2001002228A0 (en) 2001-09-30
NO20013456D0 (no) 2001-07-12
WO2000042045A2 (en) 2000-07-20
EP1144415A2 (en) 2001-10-17
MXPA01007033A (es) 2003-07-21
CN1344270A (zh) 2002-04-10
EA200100774A1 (ru) 2002-02-28
IL144289A0 (en) 2002-05-23
SK9972001A3 (en) 2002-03-05
PL349348A1 (en) 2002-07-15
HUP0202932A3 (en) 2003-07-28
WO2000042045A3 (en) 2000-11-09
CA2372197A1 (en) 2000-07-20
BR9916905A (pt) 2002-01-29
HUP0202932A2 (hu) 2002-12-28
ZA200106592B (en) 2002-08-12

Similar Documents

Publication Publication Date Title
CZ20012502A3 (cs) Funkcionalizované heterocykly jako modulátory chemokinových receptorů
JP4386639B2 (ja) セロトニンアゴニストおよびアンタゴニストとしての置換されたピロロキノリン化合物およびピリドキノリン化合物
ES2223536T3 (es) Gamma-carbolinas condensadas con heterociclos sustituidas.
US5618833A (en) 1-benzyl-1,3-dihydroindol-2-one derivatives, their preparation and the pharmaceutical compositions in which they are present
US20030064991A1 (en) Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
JPH0819099B2 (ja) アザビシクロキノロンカルボン酸化合物製造用中間体
JP2008511669A (ja) 化合物
JP2008511669A6 (ja) 化合物
JP2009507795A (ja) 化合物
JP2009524690A (ja) 化合物
MXPA02000978A (es) Antagonistas del receptor de quimioquina y metodosde uso de los mismos.
JP2008531716A (ja) 化合物
DE69430752T2 (de) Tetracyclische verbindungen
JP3170584B2 (ja) 新規なイサチンオキシム誘導体類、その製造および使用
JP2012072067A (ja) 含窒素芳香族へテロ環化合物
WO2003077857A2 (en) N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
DE69415307T2 (de) 4-arylisoindol-analgetika
AU631723B2 (en) Tricyclic-cyclic amines as novel cholinesterase inhibitors
JPH0322390B2 (ko)
JP2010053042A (ja) カリウムチャネル調節薬
EP0222703A1 (de) Hexahydro-[1]-benzo-(pyrano und thiopyrano)-[4,3-c]pyridine
Tadic et al. Probes for narcotic receptor mediated phenomena. Part 31: Synthesis of rac-(3R, 6aS, 11aS)-2-methyl-1, 3, 4, 5, 6, 11a-hexahydro-2H-3, 6a-methanobenzofuro [2, 3-c] azocine-10-ol, and azocine-8-ol, the ortho-c and the para-c oxide-bridged phenylmorphan isomers
US4283536A (en) Preparation of vincadifformine and related derivatives
JP3781698B2 (ja) 新規ピリミジン−4−オン化合物、その調製方法、およびそれらを含む医薬組成物
Osornio et al. Formal Synthesis of (±)-γ-Lycorane